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Abstract
Background: All known biological functions of the pro-inflammatory cytokine interleukin-1β (IL-1β) are mediated
by type 1 interleukin receptor (IL-1R1). IL-1β–IL-1R1 signaling modulates various neuronal functions including spinal
pain processing. Although the role of IL-1β in pain processing is generally accepted, there is a discussion in the literature
whether IL-1β exerts its effect on spinal pain processing by activating neuronal or glial IL-1R1. To contribute
to this debate, here we investigated the expression and cellular distribution of IL-1R1 in the superficial spinal
dorsal horn in control animals and also in inflammatory pain.
Methods: Experiments were performed on rats and wild type as well as IL-1R1-deficient mice. Inflammatory
pain was evoked by unilateral intraplantar injection of complete Freund adjuvant (CFA). The nociceptive
responsiveness of control and CFA-treated animals were tested daily for withdrawal responses to mechanical
and thermal stimuli before and after CFA injection. Changes in the expression of 48 selected genes/mRNAs
and in the quantity of IL-1R1 protein during the first 3 days after CFA injection were measured with the
TaqMan low-density array method and Western blot analysis, respectively. The cellular localization of IL-1R1
protein was investigated with single and double staining immunocytochemical methods.
Results: We found a six times and two times increase in IL-1R1 mRNA and protein levels, respectively, in the
dorsal horn of CFA-injected animals 3 days after CFA injection, at the time of the summit of mechanical and
thermal allodynia. Studying the cellular distribution of IL-1R1, we found an abundant expression of IL-1R1 on
the somatodendritic compartment of neurons and an enrichment of the receptor in the postsynaptic membranes of
some excitatory synapses. In contrast to the robust neuronal localization, we observed only a moderate expression of
IL-1R1 on astrocytes and a negligible one on microglial cells. CFA injection into the hind paw caused a remarkable
increase in the expression of IL-1R1 in neurons, but did not alter the glial expression of the receptor.
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Conclusion: The results suggest that IL-1β exerts its effect on spinal pain processing primarily through neuronal IL-1R1,
but it can also interact in some extent with IL-1R1 expressed by astrocytes.
Keywords: IL-1R1, Superficial spinal dorsal horn, Rodents, Inflammatory pain evoked by CFA injection,
Immunohistochemistry
Background
Interleukin-1β (IL-1β) is a major pro-inflammatory cyto-
kine, an inflammatory mediator of peripheral immune
responses [1]. In recent years, it has become clear that
IL-1β, in association with activated glial cells, modulate
also neuronal functions including spinal pain processing
[2–5]. Glial cell-produced IL-1β facilitates transmission
of noxious inputs at the spinal level [4, 6] and becomes
upregulated in the spinal cord under different chronic
pain conditions like inflammatory [4, 7–10], neuropathic
[11–13], or bone cancer pain [14]. Intrathecal IL-1β ad-
ministration induces mechanical and thermal hyperalge-
sia as well as allodynia [15–21]. IL-1β released from
astrocytes facilitates excitatory synaptic transmission in
the spinal dorsal horn [15, 21–25] by enhancing AMPA
and NMDA receptor-mediated increase of inward
current and intracellular Ca2+ concentration [9, 26–30].
In addition, IL-1β also produces long-term neuronal
plasticity in the pain circuits by inducing the phosphor-
ylation of the transcription factor cAMP-response elem-
ent binding protein [21, 31].
The biological effects of IL-1β are mediated by two
distinct receptors. The p80 or type 1 interleukin receptor
(IL-1R1), which mediates all of the known biological ef-
fects of IL-1β [32], appears to be the functional form of
the receptor [33, 34]. The p68 or type 2 interleukin re-
ceptor (IL-1R2), which has only a short 29-amino acid
cytoplasmic domain, has been identified as a non-
functional “decoy” receptor [35, 36]. Upon binding of
IL-1β to IL-1R1, an additional protein, termed IL-1 re-
ceptor accessory protein gets recruited at the cell mem-
brane to form a high-affinity binding receptor complex
with IL-1R1 leading to intracellular signaling [37, 38].
IL-1R1 has been localized widely in the central ner-
vous system including the spinal cord [7, 9, 28, 39].
There is strong evidence that IL-1R1 is expressed in
neurons [9, 13, 28, 40]. Concerning its sub-cellular
localization, IL-1R1 is distributed along dendrites and
enriched in postsynaptic membranes of excitatory synap-
ses, as shown by the high degree of co-precipitation with
postsynaptic density protein PSD-95 and NR2B subunit
of NMDA receptors [41]. Other reports, however, sug-
gest that IL-1R1 may be expressed not only in neurons
but also in glial cells [13, 28, 42–45] including astro-
cytes, activated microglia, oligodendrocytes, and epen-
dymal cells [43, 46].
According to the prevailing view, the synaptic effects of
IL-1β are mediated by direct actions on neurons [47–49].
In the superficial spinal dorsal horn, however, Gruber-
Schoffnegger et al. [45] reported that the synaptic effects
of IL-1β were not mediated directly via activation of neur-
onal IL-1R1, but rather indirectly via IL-1R1 being
expressed on glial cells. According to this alternative sig-
naling pathway, IL-1β primarily acts on glial IL-1R1. Acti-
vation of glial cells leads to the release of further
cytokines, chemokins, and gliotransmitters [50, 51] which
may amplify glutamatergic synaptic transmission trigger-
ing long-term potentiation (LTP) at C-fiber synapses and
hyperalgesia [45]. Because of this contradiction in the
interpretation of the effects of IL-1β on nociceptive infor-
mation processing, here we intended to reinvestigate the
expression and cellular distribution of IL-1R1 in the
superficial spinal dorsal horn. We intended to explore the
expression pattern of IL-1R1 on neurons and glial cells in




Experiments were performed on male Wistar rats
(Gödöllő, Hungary) and wild type as well as IL-1R1-
deficient mice (B6.129S7-Il1r1 tm1/mx,/J stock #
:003245) created by Labow et. al. (1997) and purchased
from Jackson Laboratories (Bar Harbor, ME, USA). All
animal study protocols were approved by the Animal
Care and Protection Committee at the University of
Debrecen and were carried out in accordance with the
European Community Council Directives. Animals
were housed individually in a temperature-controlled
(24 °C) colony room and maintained on a 12 h/12 h
light/dark cycle. Food and water were provided ad libi-
tum. Animals were divided into three experimental
groups: Experimental group 1 (15 rats, 6 wild type, and
6 IL-1R1-deficient mice): injection of 100 and 50 μl
complete Freund-adjuvant (CFA) into the plantar sur-
face of the right hind paw of rats and mice, respectively.
Experimental group 2 (9 rats, 6 wild type, and 6 IL-
1R1-deficient mice): injection of 100 and 50 μl physio-
logical saline into the plantar surface of the right hind
paw of rats and mice, respectively. Experimental group
3 (15 rats, 6 wild type, and 6 IL-1R1 deficient mice): an-
imals without any treatment were used as controls.
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Behavioral tests
All animals were tested for withdrawal responses to nox-
ious mechanical and thermal stimuli using a dynamic
plantar aestesiometer (Ugo Basile, Comerio, VA, Italy)
and a Plantar Test Instrument—Hargreaves Apparatus
(Ugo Basile, Comerio, VA, Italy), respectively. The mech-
anical withdrawal threshold (MWT) and the thermal
withdrawal latency (TWL) for both hind paws were
measured before CFA or saline injection, and the tests
were repeated daily after CFA injection. On the six
animals in each experimental groups which were used
only for behavioral testing, the measurements were
carried out till post-injection day 11, whereas on ani-
mals which were used for other experiments, MWT
and TWL were measured only until post-injection
day 3, when the summit of mechanical and thermal
sensitivities were detected.
Measurement of mechanical sensitivity
Animals were placed upon a network platform and cov-
ered with a Perspex enclosure that rendered the animals
unrestrained for the duration of the measurement. The
hind paw of the animal was positioned above a von
Frey-type filament with a tip diameter of about 0.5 mm.
The filament exerted an increasing pressure to the plan-
tar surface until the animal removed its paw. At this
point, the measurement was terminated and the actual
force at which paw withdrawal occurred was recorded.
The measurement was repeated five times in each case.
From the 30 experimental data (six animals in each
group and five measurements on each hind paw), the
mean value and standard error of mean (SEM) were cal-
culated. Statistical differences among the data were cal-
culated according to the Kruskal-Wallis test.
Measurement of thermal sensitivity
Animals were placed upon a plastic platform and cov-
ered with a Perspex enclosure that rendered the ani-
mals unrestrained for the duration of the measurement.
The hind paw of the animal was positioned above an
infrared light source which was focused onto the plan-
tar surface. The illumination which exerted a heat
stimulus to the plantar surface was applied until the
animal removed its paw. At this point the measurement
was terminated and the actual time elapsed until the
withdrawal of the paw was recorded. The measure-
ments were repeated five times in each case. From the
30 experimental data (six animals in each group and
five measurements on each hind paw), the mean values
and standard error of means were calculated. Statistical
differences among the data were calculated according
to the Kruskal-Wallis test.
TaqMan low-density array
After the exposure of the spinal cord with serial lamin-
ectomy, the L3–L5 lumbar segments of the spinal cord
were dissected out from three rats in each experimental
group 3 days after CFA injection. The dorsal horn ipsi-
lateral to the site of injection was separated from the rest
of the spinal cord and was kept for further processing.
Immediately after tissue removal RNA was isolated
(RNeasy Lipid tissue kit, Qiagen, Maryland, USA), and
cDNA library was created (High Capacity cDNA Reverse
Transcription Kit, Applied Biosystems, Foster City, USA,
catalog no.: 4368814). RNA quality was tested by Agilent
microelectrophoresis system and by Nanodrop photo-
metric analysis. One hundred monograms of cDNA was
loaded on each port of the custom designed TaqMan
low-density array card (TLDA; Applied Biosystems,
Foster City, USA) containing 48 gene format including
the gene encoding IL-1R1 and three housekeeping as
well as one mandatory control gene (the list of genes is
shown in Table 1). PCR reactions were performed by
means of ABIPrism7000 real-time PCR system (Applied
Biosystems, catalog no.: 4328895). The ABI TaqMan so-
dium dodecyl sulfate (SDS) software was utilized to ob-
tain the threshold cycle (Ct) values. Data have been
obtained from three separate experiments.
The gene expression values have been calculated
according to the 2−ΔΔCt comparative threshold cycle
method [52]. First, the threshold cycle (Ct), indicating
the cycle number by which the amount of the amplified
target reaches a fixed threshold, was defined for all in-
vestigated genes (Table 1). Then, the Ct of each gene has
been normalized (ΔCt) to the average Ct of the three en-
dogenous housekeeping genes (GAPDH, ARBP, PPIA)
according to the formula: ΔCt = Ct (target gene) − Ct
(housekeeping genes). The ΔCt values were calculated
from tissue samples obtained from both the control and
CFA-injected animals. Making a relative comparison be-
tween PCR signals of the target gene transcripts in tissue
samples obtained from the CFA-injected animals to that
obtained from the control animals, ΔΔCt values were
calculated according to the following equation: ΔΔCt
=ΔCt (treated samples) −ΔCt (control samples). Finally,
obtaining a relative quantitative value proportional to
the changes of the RNA levels evoked by CFA injections,
the final value of 2−ΔΔCt (fold change over the control
level) [52] was calculated. Statistical significance of the
changes was calculated according to the ANOVA statis-
tical probe.
Western blot analysis
The changes in the quantity of IL-1R1 protein during
the first 3 days after CFA injection were measured by
Western blot analysis. The spinal cord tissue sample col-
lection procedure was the same as that described at the
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Table 1 List of genes the RNA transcripts of which were tested with the TaqMan Low Density Array
# Gene symbol Full name Assay ID
1 Grin1 Ionotropic glutamate receptor NMDA1 Grin1-Rn00433800_m1
2 Grin2a Ionotropic glutamate receptor NMDA2A Grin2a-Rn00561341_m1
3 Grin2c Ionotropic glutamate receptor NMDA2C Grin2c-Rn00561364_m1
4 Gria2 Ionotropic glutamate receptor, AMPA2 Gria2-Rn00568514_m1
5 Gria3 Ionotropic glutamate receptor, AMPA3 Gria3-Rn00583547_m1
6 Gria4 Ionotropic glutamate receptor, AMPA4 Gria4-Rn00568544_m1
7 Grm5 Metabotropic glutamate receptor 5 Grm5-Rn00566628_m1
8 Htr1a 5-Hydroxytryptamine (serotonin) receptor 1A Htr1a-Rn00561409_s1
9 Htr2a 5-Hydroxytryptamine (serotonin) receptor 2A Htr2a-Rn00568473_m1
10 Htr3a 5-Hydroxytryptamine (serotonin) receptor 3a Htr3a-Rn00577803_m1
11 Htr7 5-Hydroxytryptamine (serotonin) receptor 7 Htr7-Rn00576048_m1
12 Gabra3 Gamma-aminobutyric acid (GABA-A) receptor, alfa 3 Gabra3-Rn00567055_m1
13 Gabrb2 Gamma-aminobutyric acid (GABA-A) receptor, beta 2 Gabrb2-Rn00564149_m1
14 Gabrb3 Gamma-aminobutyric acid (GABA-A) receptor, beta 3 Gabrb3-Rn00567029_m1
15 Gabbr1 Gamma-aminobutyric acid (GABA) B receptor 1 Gabbr1-Rn00578911_m1
16 Gabbr2 Gamma-aminobutyric acid (GABA) B receptor 2 Gabbr2-Rn00582550_m1
17 Gad2 Glutamic acid decarboxylase 2 Gad2-Rn00561244_m1
18 Gad1 Glutamic acid decarboxylase 1 Gad1-Rn00566593_m1
19 Glra1 Gglycine receptor, alpha 1 Glra1-Rn00565582_m1
20 Glra2 Glycine receptor, alpha 2 Glra2-Rn00561280_m1
21 Glra3 Glycine receptor, alpha 3 Glra3-Rn01638847_m1
22 Glrb Glycine receptor, beta Glrb-Rn00583966_m1
23 Slc6a5 Glycine transporter 2 Slc6a5-Rn01475607_m1
24 Il6ra Interleukin 6 receptor, alpha Il6ra-Rn00566707_m1
25 Il1r1 Interleukin 1 receptor 1 Il1r1-Rn00565482_m1
26 Cx3cl1 Chemokine (C-X3-C) ligand 1 Cx3cl1-Rn00593186_m1
27 Cx3cr1 Chemokine (C-X3-C) receptor 1 Cx3cr1-Rn00591798_m1
28 Cxcl12 Chemokine (C-X-C motif) ligand 12 Cxcl12-Rn00573260_m1
29 Cxcr4 Chemokine (C-X-C motif) receptor 4 Cxcr4-Rn00573522_s1
30 Ccl2 Chemokine (C-C motif) ligand 2 Ccl2-Rn00580555_m1
31 Slc12a5 Potassium-chloride cotransporter 2 Slc12a5-Rn00592624_m1
32 Slc12a2 Sodium-potassium-chloride cotransporter member 1 Slc12a2-Rn00582505_m1
33 Hcn1 Hyperpolarization activated cyclic nucleotide-gated channel 1 Hcn1-Rn00584498_m1
34 Hcn2 Hyperpolarization activated cyclic nucleotide-gated channel 2 Hcn2-Rn01408575_gH
35 Hcn3 Hyperpolarization activated cyclic nucleotide-gated channel 3 Hcn3-Rn00586666_m1
36 Hcn4 Hyperpolarization activated cyclic nucleotide-gated channel 4 Hcn3-Rn00586666_m1
37 Scn9a Voltage-gated Na channel, 9 Scn9a-Rn00591020_m1
38 Scn10a Voltage-gated Na channel, 10 Scn10a-Rn00568393_m1
39 NAPE-PLD N-acil-phoszphatidylethanolamine-hydrolising phospholipase D NAPE-PLD-Rn01786262_m1
40 Faah Fatty acid amid hydrolase Faah-Rn00577086_m1
41 Ntrk2 Neurotrophic tyrosine kinase, receptor, 2 Ntrk2-Rn00820626_m1
42 Bdnf Brain derived neurotrophic factor Bdnf-Rn00560868_m1
43 Pkcg Protein kinase C, gamma Prkcc-Rn00440861_m1
44 Mapk8 Mitogene-activated protein kinase 8 (JNK) Mapk8-Rn01453358_m1
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TLDA analysis. Tissue samples were sonicated in
20 mM Tris (pH 7.4) lysis buffer supplemented with
protease inhibitors (4 mM EDTA, 2.5 mM EGTA, 2 nM
PMSF, 26 μM benzamidine, 8 μM pepstatine A, 2 μg/ml
soybean trypsine inhibitor, 2 μg/ml leupeptine, 2 μg/ml
aprotinin). The cell debris were removed by centrifuga-
tion (10 min at 1500 rcf and 4 °C), then the supernatant
was again centrifuged (20 min at 12,000 rcf and 4 °C).
The pellet was re-suspended in lysis buffer containing
1% Triton X-100 and 0.1% SDS. The samples were
stored at −70 °C until use.
The protein concentration of the samples was deter-
mined using the detergent-compatible BCA assay
(Pierce, Rockford, USA). The samples were dissolved in
reducing sample buffer (50 μg protein/lane) and run on
10% SDS-polyacrylamide gels [53]. The separated pro-
teins were electrophoretically transferred onto polyvinili-
dene difluoride (PVDF) membrane (Millipore, Bedford,
USA). The membranes were blocked with 10% bovine
serum albumin (Sigma, St Louis, MO, USA) in Tween/
Tris-buffered salt solution (TTBS) solution (20 mM
TRIS, 500 mM NaCl, pH 7.5, 0.05% Tween-20) for 2 h
at room temperature and then were incubated with anti-
IL-1R1 receptor antibody raised in goat (1:500, RnD Sys-
tems, Minneapolis, USA, catalog no.: AF-771) overnight
at 4 °C. After extensive washing with TTBS, the blots
were incubated with a rabbit-anti-goat IgG secondary
antibody conjugated with HRP (1:1000 DakoCytomation,
Glostrup, Denmark catalog no.: P0448). The immuno-
stained protein bands were visualized with a diamino-
benzidine chromogen reaction.
For quantitative analysis, the blots were also probed
for a loading control of β-tubulin. The blots were treated
first with a mouse-anti-β-tubulin antibody (1:2000 dilu-
tion, Sigma, catalog no.: T8328) followed by a rabbit-
anti-mouse IgG conjugated with HRP (1:500 dilution,
DakoCytomation, catalog no.: P0447) secondary anti-
body. The immunostaining was developed by an amino-
ethyl carbasole substrate kit (Vector, Burlingame, CA,
USA, catalog no.: SK4200). Quantification of the immu-
noblots was performed using Image J software. The op-
tical density values obtained for IL-1R1 were normalized
to density values acquired for β-tubulin. The Western
blot analysis and the calculation of the relative quantity
of IL-1R1 receptor protein were conducted on three in-
dependent preparations. From quantitative data, mean
and SEM values were calculated. Data obtained from
control and CFA-injected samples were compared using
a one-way ANOVA statistical probe.
Immunohistochemistry
Tissue preparation
Immunohistochemical experiments were performed on
three controls and three CFA-injected adult male Wistar
rats (250–300 g) 3 days after CFA injection. The animals
were deeply anesthetized with sodium pentobarbital
(50 mg/kg i.p.) and transcardially perfused first with
Tyrode’s solution oxygenated with a mixture of 95% 02
and 5% CO2, followed by a fixative containing 4% para-
formaldehyde in 0.1 M phosphate buffer (PB; pH 7.4).
The L4 lumbar segment of the spinal cord was removed
from all animals, post-fixed in the same fixative over-
night, and immersed in 10 and 20% sucrose dissolved in
0.1 M PB until they sank. After freeze-thawing in liquid
nitrogen, 50-μm-thick serial sections were cut on a
Vibratome.
Single immunoperoxidase staining
Free-floating sections were first incubated with an anti-
body raised against IL-1R1 in goat (diluted 1:100; RnD
Systems) for 2 days at 4 °C. The sections were then
transferred into biotinylated rabbit anti-goat IgG (1:200,
Vector Laboratories, Burlingame, CA, USA, catalog no.:
PK-4001) for 5–6 h. Thereafter, they were treated with
an avidin-biotinylated horseradish peroxidase complex
(diluted 1:100, Vector Laboratories, Burlingame, CA,
USA, catalog no.: PK-4001) and the immunoreaction
was completed with a diaminobenzidine chromogen re-
action. Before the antibody treatments, the sections were
kept in 20% normal rabbit serum (Vector Laboratories,
Burlingame, CA, USA, catalog no.: Z0819) for 50 min.
The antibodies were diluted in 10 mM Tris phosphate-
buffered isotonic saline (TPBS; pH 7.4) to which 1% nor-
mal rabbit serum (Vector Laboratories, Burlingame, CA,
USA) was added. Sections were mounted on glass slides
and covered with DPX neutral medium.
Controls
As a part of the immunohistochemical protocol, we
tested the specificity of the primary antibody on tissue
sections by treating the diluted anti-IL-1R1 with recom-
binant rat IL-1R1 protein (Sino Biological Inc, Beijing,
Table 1 List of genes the RNA transcripts of which were tested with the TaqMan Low Density Array (Continued)
45 GAPDH Glyceraldehyde-3-phosphate dehydrogenase Gapdh-Rn99999916_s1
46 ARBP Acidic ribosomal phosphoprotein P0 Arbp-Rn00821065_g1
47 PPIA Peptidylprolyl isomerase A Ppia-Rn00690933_m1
Mandatory control gene:
48 18S rRNA 18S ribosomal RNA 18S-Hs99999901_s1
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China, catalog no.: 80028R08H50) for the purpose of
antibody adsorption. The recombinant IL-1R1 peptide
was mixed with the antibody (1 μg peptide per 1 μg anti-
body), left at 4 °C for 16–18 h and then centrifuged.
Free-floating sections were incubated according to the
single immunoperoxidase staining protocol by using the
antibody against IL-1R1 treated with the IL-1R1 peptide
as primary serum. Under these conditions, specific im-
munostaining was completely abolished (Fig. 1a).
To obtain a more global view about the specificity of
the anti-IL-1R1 antibody, a Western blot analysis was
performed as described in the section “Western blot
analysis.” The immunostaining of the blot revealed only
one immunoreactive band at molecular weight of
80 kDa (Fig. 1b) corresponding to the molecular weight
of IL-1R1 [36].
To check the specificity of the immunostaining
method, sections were treated by the immunocytochem-
ical procedure as described earlier, with the primary
antibody omitted or replaced with normal rabbit serum
(diluted 1:100). Under these conditions, no peroxidase
reaction was observed.
Double immunofluorescent staining
A double-immunostaining protocol was performed to
study the co-localization of IL-1R1 with various neur-
onal and glial markers. Free-floating sections were first
incubated with a mixture of antibodies that contained
goat anti-IL-1R1 (diluted 1:100, R&D Systems) and one
of the following antibodies: guinea-pig anti-calcitonin
gene-related peptide (CGRP; diluted 1:2000, Peninsula
Labs,, San Carlos, CA, USA, catalog no.: T-5027), bio-
tinylated isolectin B4 (IB4; diluted 1:2000, Sigma, catalog
no.: 121414), guinea-pig anti-vesicular glutamate trans-
porter 2 (VGLUT2; diluted 1:2000, Chemicon,
Temecula, CA, USA, catalog no.: AB2251), mouse anti-
vesicular gamma-amino butyric acid transpofter (VGAT;
diluted 1:200, Synaptic Systems, Goettingen, Germany,
catalog no.: 131011), mouse anti-glial fibrillary acidic
protein (GFAP; diluted 1:1000, Chemicon, catalog no.:
MAB3402), mouse anti-CD11b (1:500, Bachem Holding,
Bubendorf, Switzerland, catalog no.: T-3102), rabbit anti-
potassium-chloride co-transporter 2 (KCC2; 1:2000,
Upstate Biotechnology Inc Lake Placid NY New York,
catalog no.: 07-432), mouse anti-postsynaptic density
protein 95 (PSD-95; 1:100, Frontier, Geumcheon-Gu,
Seoul, Korea, catalog no.: AB2723), or mouse anti-
gephyrin (diluted 1:100, Synaptic Systems, catalog no.:
147021) for 2 days at 4 °C. The sections were then trans-
ferred for an overnight treatment into the mixture of
donkey anti-goat IgG conjugated with Alexa Fluor 555
(diluted 1:1000, Molecular Probes, Eugene, OR, USA, cata-
log no.: A21432), and donkey anti-guinea-pig IgG conju-
gated with Alexa Fluor 488 (diluted 1:1000, Molecular
Probes, Life Technologies catalog no.: A11055), streptavidin
conjugated with Alexa Fluor 488 (diluted 1:1000, Molecular
Probes, catalog no.: S11223), donkey anti-mouse conju-
gated with Alexa Fluor 488 (diluted 1:1000, Molecular
Probes, catalog no.: A31570), or donkey anti-rabbit conju-
gated with Alexa Fluor 488 (diluted 1:1000, Molecular
Probes, catalog no.: A21206) for 5–6 h at room
temperature. Before the antibody treatments, the sections
were kept in 10% normal donkey serum (Vector
Labs., Burlingame, California, USA, S30-100ML) for
50 min. Antibodies were diluted in 10 mM TPBS (pH
7.4) to which 1% normal donkey serum (Vector Labs.,
Fig. 1 Specificity of the anti-IL-1R1 antibody and distribution of IL-1R1 immunoreactivity in the spinal dorsal horn. a Adsorption of anti-IL-1R1 antibody
to recombinant IL-1R1 peptide completely abolished the immunostaining. b Western blot analysis reinforces the specificity of the anti-IL-1R1 antibody.
The single immunoreactive band indicates that the antibody detects a protein with a molecular mass of ~80 kDa that corresponds to the molecular
weight of IL-1R1. c, d Micrographs showing immunoreactivity for IL-1R1 in control (c) and CFA-injected rats (d) 3 days after CFA-injection. Bars 100 μm
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Burlingame, California, USA) was added. Sections were
mounted on glass slides and covered with Vectashield
mounting medium (Vector Labs., Burlingame, California,
USA, H-1000).
Confocal microscopy and quantitative analysis
Single 1-μm-thick optical sections were scanned with an
Olympus FV1000 confocal microscope. Scanning was
carried out with a ×40 oil-immersion lens (NA 1.3). The
confocal settings (laser power, confocal aperture and
gain) were identical for all means, and care was taken to
ensure that no pixels corresponding to puncta immuno-
stained for IL-1R1 and the other markers were saturated.
The scanned images were processed by Adobe Photoshop
CS3 software. By filtering the background staining out
with a high-pass intensity filter, threshold values were set
for both IL-1R1 and the other markers. The co-
localization of IL-1R1 with neuronal and glial markers was
quantitatively analyzed in the double-stained sections. A
10 × 10 standard square grid with an edge-length of 4 μm
was put onto confocal images obtained from 1-μm-thick
single optical sections. IL-1R1-immunostained spots over
the edges of the standard grid were counted in laminae I
and II. The selected IL-1R1-immunostained spots were
then examined to determine whether they were located
within the confines of areas immunoreactive for the
axonal (CGRP, IB4-binding, VGLUT2, VGAT), glial (GFAP,
CD11b), and postsynaptic membrane (PSD95, gephyrin)
markers. In case of sections double-stained for IL-1R1 and
KCC2, the selected IL-1R1-immunostained spots were
checked to define whether they were aligned along KKC2-
immunostained membranes (considered as somatodendri-
tic membrane expression of IL-1R1) or located within
areas surrounded by KCC2-immunostained membranes
(considered as cytoplasmic expression of IL-1R1 at the
somatodendritic compartment of neurons). Three ran-
domly selected confocal sections were analyzed from each
animal. Thus, the calculation of quantitative data, mean
values, and SEM, was based on the investigation of nine
sections. Data obtained from control and CFA-injected
animals were compared. Statistical differences between the
two experimental groups were computed using a Mann-
Whitney test.
Results
Complete Freund adjuvant-evoked inflammation as a
model of inflammatory pain
We intended to explore the expression pattern of IL-1R1
in the superficial spinal dorsal horn both in naïve ani-
mals and in inflammatory pain. Since the complete
Freund adjuvant (CFA)-evoked inflammatory pain model
has already been established in our laboratory [54], we
selected this pain model for our experiments. As we pre-
dicted it from our previous studies [54], subcutaneous
injection of CFA into the right hind paw evoked a strong
inflammation and the development of a prominent
mechanical allodynia.
The mechanical withdrawal thresholds (MWT) of the
untreated control animals and those of the non-treated
left hind paw of experimental animals were very similar
in all animals throughout the entire duration of the ex-
periment (Fig. 2). The CFA injection resulted in a sud-
den drop in MWT of the treated right hind paw. The
decline in MWT values peaked at post-injection days 2
and 3. From post-injection day 4, MWT values showed a
continuous elevation and they returned back to the con-
trol values by post-injection day 11 (Fig. 2).
Overexpression of IL-1R1 in CFA-evoked inflammatory pain
Although the expression of IL-1R1 has already been
demonstrated in the spinal cord [43, 46], there has been
no attempt to follow the potential changes in the expres-
sion of the receptor in inflammatory pain. Thus, we
intended to explore how the expression of the receptor
changes in CFA-induced inflammatory pain at the level
of both mRNA and protein, and how the changes in the
quantities of the receptor protein can be visualized with
the aid of immunohistochemical staining which is essen-
tial for the cellular localization of the receptor.
Fig. 2 Mechanical withdrawal threshold of rats during the course of
CFA-induced inflammation of the hind paw. The histogram shows
the mechanical withdrawal threshold (MWT) on both hind limbs of
control animals and animals receiving CFA injection into the right
hind paw. Note that MWT values appeared to be remarkably stable
throughout the entire length of the experimental period in control
animals and in the untreated left hind paw of animals receiving CFA
injection into the right hind paw. However, CFA injection resulted in a
substantial drop in MWT values in the right hind paw of experimental
animals which peaked at post-injection days 2 and 3 and returned
back to normal values by post-injection day 11. Data are shown
as mean ± SEM
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To find out how IL-1R1 receptor mRNA level changes
in the spinal dorsal horn, a TILDA essay was performed.
Comparing the mRNA levels of tissue samples obtained
from the dorsal horn of control animals and from the
dorsal horn of CFA-injected animals ipsilateral to the
CFA injection at post-injection day 3 (at the peak of
mechanical allodynia), we observed a highly significant,
approximately six times increase in the IL-1R1 mRNA
(p = 0.0002) in the experimental animals (Table 2).
To define whether CFA injection-evoked changes in
the IL-1R1 mRNA expression were confined only to the
ipsi-lateral spinal cord, we performed the TILDA assay
also on tissue samples obtained from the dorsal horn of
CFA-injected animals contra-lateral to the CFA injec-
tion. We found that although at a bit lower extent and
with higher inter-animal variations, the expression of IL-
1R1 mRNA also showed an elevation in the contra-
lateral dorsal horn, indicating that the increase in IL-1R1
mRNA is not confined to the regions of the spinal gray
matter receiving sensory innervations from the inflamed
area of the skin, but the local paw inflammation may
evoke a more general effect on spinal pain processing.
Although this finding was very exciting, we intended to
focus the present study to the dorsal horn ipsilateral to
the CFA-evoked inflammation. For this reason, the rest
of the experiments had been conducted exclusively on
spinal cord samples obtained from the dorsal horn ipsi-
lateral to the CFA injection.
To demonstrate this increase also at the level of the
receptor protein, we carried out Western blot analysis
on tissue samples obtained from the dorsal horn of the
control animals and from the dorsal horn of CFA-
injected animals ipsilateral to the CFA injection at post-
injection day 3 (Fig. 3a). A densitometric analysis
showed an approximately 1.5-fold increase in the IL-1R1
protein level (p = 0.029) in the experimental animals
(Fig. 3b).
Concerning the distribution of IL-1R1 in the spinal
dorsal horn, peroxidase-based single immunostaining re-
vealed a punctuate immunostaining in the dorsal horn
(Fig. 1c). The staining within laminae I–II was a bit
stronger than that in deeper laminae. The heaviest stain-
ing was confined to the inner lamina II, which appeared
as a densely immunostained band traversing the entire
medio-lateral extent of the dorsal horn (Fig. 1c). CFA-
evoked inflammation induced an increase in the density
of the immunostaining throughout the entire dorsal
horn including laminae I–II ipsilateral to the injection
site (Fig. 1d). The immunostaining in the inner lamina II
also became more abundant (Fig. 1d).
Table 2 List of genes that showed statistically significant changes in tissue samples obtained from the spinal dorsal horn of
CFA-injected animals ipsilateral to the CFA injection at post-injection day 3 (at the peak of mechanical allodynia)
Gene symbol Gene name ΔCt control ΔCt treated Fold change 2-ΔΔCt p value
Faah fatty acid amid hydrolase 6.4 ± 0.01 6.7 ± 0.1 0.78 0.0368
Gria2 ionotropic glutamate receptor, AMPA2 3.0 ± 0.24 3.3 ± 0.06 0.77 0.0447
il1r1 interleukin 1 receptor 1 14.7 ± 0.001 12.1 ± 0.002 6.02 0.0002
Nape-pld N-acyl-phosphatidylethanolamine-hydrolising phospholipase D 7.0 ± 0.06 6.9 ± 0.17 1.11 0.0016
Values obtained from CFA-injected animals were compared to values obtained from control animals. Note that we observed a highly significant, approximately six
times increase in the quantity of IL-1R1 receptor mRNA in the experimental animals
Fig. 3 CFA-evoked inflammation of the hindpaw initiates an
overproduction of IL-1R1 protein in the spinal dorsal horn of rats.
a Representative immune-blots showing immunoreactive bands
for IL-1R1 and β-tubulin (loading control) in Western blots of tissue
samples obtained from the L3–L5 lumbar segments of the spinal dorsal
horn of the control and CFA-injected animals at post-injection day 3. b
Histogram showing the optical densities of IL-1R1 immunostained
bands (see on insert a) calculated in proportion to the optical densities
of β-tubulin (loading control) immunostained bands (see on insert a).
IL-1R1 protein level was found to be significantly higher than
the control value (p = 0.029). Data are shown as mean ± SEM
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Mechanical and thermal allodynia does not develop in
the lack of IL-1R1
The substantial increase in IL-1R1 expression in the
spinal dorsal horn evoked by CFA injection into the hind
paw seems to be in full agreement with earlier observa-
tions showing that IL-1β is also upregulated in inflam-
matory pain [4, 7–10]. In addition to IL-1β–IL-1R1
signaling, however, there are a number of other factors
that also contribute to the development of hyperalgesia
and allodynia in inflammatory pain (for review see
McMahon and Koltzenburg, 2006) [55]. Thus, we
intended to explore how much is the contribution of the
IL-1R1-mediated signaling events to the development of
mechanical and thermal allodynia in inflammatory pain.
We injected CFA into the right hind paw of wild type
and IL-1R1 knockout (B6.12957-IL1r1 tm1/mx/J, stock
#:003245) mice and followed the development of mech-
anical and thermal allodynia by measuring the me-
chanical withdrawal threshold (MWT) and thermal
withdrawal latency (TWL) values daily from the day of
injection till post-injection day 11. Instead of CFA, some
animals received an injection of physiological saline
(sham-injected animals). Comparing the MWT values
measured in untreated and sham-injected animals to
those observed in IL-1R1 knockout mice, we found that
the IL-1R1 knockout animals showed a higher sensitivity
for acute mechanical stimulation than the naïve animals.
The MWT values of the untreated control and those of
the IL-1R1-depleted mice were very stable throughout
the entire duration of the experiment (Fig. 4a). The
values varied between 4.1–5.0 g with an average of
4.81 ± 0.29 g and between 3.0–5.0 g with an average
of 3.94 ± 0.51 g in case of the wild type and the IL-
1R1 knockout animals, respectively (Fig. 4a). The dif-
ference between the basal values of the wild type and
knockout animals turned out to be highly significant
(p = 0.0000002). Injection of physiological saline into
the right hind paw did not cause any detectable
change in MWT values (Fig. 4a). The CFA injection,
however, resulted in a sudden drop in MWT of the
treated right hind paw of the wild type animals. The
decline peaked at post-injection day 4 when MWT
values dropped to 1.68 ± 0.06. Then, MWT values
showed a continuous elevation and they returned back
to the control values by post-injection days 10–11 (Fig. 4).
The IL-1R1 knockout animals showed only a slight de-
cline in MWTvalues to CFA injection, and even this mod-
erate decline lasted only for a week after CFA injection
(Fig. 4a). The degree of decrease in the MWT values
reached the statistically significant level only between
post-injection days 1–7 in the IL-1R1 knockout animals
(p = 0.00004–0.006). However, the difference between
MWT values measured after the injection of CFA in
wild type and IL-1R1 knockout animals were highly
significant from post-injection day 1 till post-injection
day 9 (p = 0.000004–0.01).
The course and degree of thermal allodynia evoked by
CFA injection was similar to that of mechanical allody-
nia both in the wild type and IL-1R1 knockout animals.
The basal TWL values, however, did not show any dif-
ference between the wild type and IL-1R1 knockout ani-
mals. The TWL values were very stable throughout the
entire duration of the experiment and varied between
4.9 and 10.2 s with an average of 7.47 ± 1.22 s, and be-
tween 6.3 and 10.0 s with an average of 8.15 ± 0.85 s in
case of the wild type and the IL-1R1 knockout animals,
Fig. 4 Mechanical withdrawal threshold and thermal withdrawal
latency of wild type and IL-1R1 knockout mice during the course of
CFA-induced inflammation of the hind paw. a The histogram shows
the mechanical withdrawal threshold (MWT) of wild type (BL6) and
IL-1R1 knockout (IL-1R1 KO) mice receiving different treatments in
the three experimental groups: group (1) complete Freund-adjuvant
(CFA) injection (BL6 CFA, IL-1R1 KO CFA); group (2) physiological
saline injection (BL6 sham, IL-1R1 KO sham); and group (3) without
any treatment (BL6 control, IL-1R1 KO control). Measurements were
made only on the right hind paw which received the physiological
saline or CFA injections. b The histogram shows the thermal withdrawal
latency (TWL) of wild type (BL6) and IL-1R1 knockout (IL-1R1 KO) mice
receiving different treatments in the three experimental groups: group
(1) complet Freund-adjuvant (CFA) injection (BL6 CFA, IL-1R1 KO CFA);
group (2) physiological salt solution injection (BL6 sham, IL-1R1 KO
sham); and group (3) without any treatment (BL6 control, IL-1R1 KO
control). Measurements were made only on the right hind paw which
received the physiological saline or CFA injections. Data are shown
as mean ± SEM
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respectively (Fig. 4b). Injection of physiological saline
into the right hind paw did not cause any detectable
change in TWL values (Fig. 4b). The CFA injection,
however, resulted in a sudden drop in TWL of the
treated right hind paw of the wild type animals. The de-
cline peaked at post-injection days 2 and 3 when TWL
values dropped to 1.74 ± 0.1 s and 1.72 ± 0.08 s, respect-
ively. Then, TWL values showed a continuous elevation,
and they returned back to the control values by post-
injection days 9–10 (Fig. 4b). The IL-1R1 knockout ani-
mals showed only a slight decline in TWL values to CFA
injection, and even this moderate decline lasted only for
a week after CFA injection (Fig. 4a). The degree of de-
crease in the TWL values reached the statistically signifi-
cant level only between post-injection days 1–7 in the
IL-1R1 knockout animals (p = 0.0005–0.029). However,
the difference between TWL values measured after the
injection of CFA in wild type and IL-1R1 knockout ani-
mals was highly significant from post-injection day 1 till
post-injection day 9 (p = 0.000003–0.021).
IL-1R1 is expressed on both neurons and glial cells
The robust difference in the degree of mechanical and
thermal sensitivity evoked by CFA-induced inflammation
in wild type and IL-1R1 knockout animals indicates that
IL-1R1-mediated signaling play a major role in the de-
velopment of inflammatory pain. For the proper inter-
pretation of the mechanism of IL-1R1 activation,
however, it is necessary to obtain a proper knowledge
about the expression pattern of the receptor on neurons
and glial cells. It has already been reported that IL-1R1
is expressed on both neurons [8, 9, 13, 40] and glial cells
[13, 28, 42–46], but nothing is known about the relative
distribution of the receptor on these two distinct cell
populations. Because of the conflict in the presently
available interpretations of neuronal and glial contribution
to the net effect of IL-1R1-mediated signaling events on
the activities of neuronal assemblies [45, 47–49], we
intended to explore the proportional distribution of IL-
1R1 on neurons and glial cells. Thus, we performed
double immunostainings in which we investigated the
localization of IL-1R1 immunoreactive spots on neurons
and glial cells immunostained for markers specific for
various axon terminals, perikarya and dendrites of
neurons, postsynaptic membranes of excitatory, and
inhibitory synaptic contacts, as well as astrocytes and
microglial cells.
Localization of IL-1R1 on axon terminals
To study the expression of IL-1R1 on central axon ter-
minals of peptidergic and non-peptidergic nociceptive
primary afferents as well as axon terminals of putative
glutamatergic and GABAergic spinal neurons, we inves-
tigated the co-localization of the receptor with calcitonin
gene-related peptide (CGRP) and isolectin B4 (IB4)-
binding as well as vesicular glutamate transporter type 2
(VGLUT2) and vesicular gamma amino butyric acid
transporter (VGAT), markers selectively labeling axon
terminals that we intended to identify [56–60].
Confirming results of previous studies [57, 59, 61–66],
we have revealed strong punctate immunostainings for
CGRP, VGLUT2, and VGAT in laminae I–II, and IB4-
binding also labeled a large number of axon terminals in
lamina IIi. Despite of the extensive and intense axonal
staining, the double-stained specimen showed almost a
complete segregation between IL-1R1 and the axonal
markers (Figs. 5a–d, 6). From the 1099, 1331, 1333, and
1001 IL-1R1 immunoreactive dots recovered from the
nine investigated sections immunostained for CGRP,
IB4-binding, VGLUT2 or VGAT only 1 (0.1 ± 0.01%), 4
(0.3 ± 0.10%), 16 (1.2 ± 0.46%) ,and 1 (0.1 ± 0.04%) of IL-
1R1 immunoreactive puncta were recovered on axon
terminals immunoreactive for CGRP, binding IB-4, and
immunoreactve for VGLUT2 and VGAT, respectively.
Localization of IL-1R1 on the somatodendritic membrane of
neurons
From the members of the cation-chloride cotransporter
family which are primarily responsible for the regulation
of intracellular chloride concentration of cells [67–71]
the potassium-chloride co-transporter 2 (KCC2) has been
shown to be expressed only on neurons [67, 72–76]. It ap-
pears to be primarily responsible for the Cl-mediated hy-
perpolarizing postsynaptic currents evoked by GABAergic
and glycinergic transmission [70, 76–79], and its extensive
expression has convincingly been demonstrated on the
somatodendritic membranes but not on axon terminals of
spinal dorsal horn neurons [80–82].
Thus, to study the expression of IL-1R1 on the soma-
todendritic compartment of neurons, we labeled the
somatodendritic cell membrane with an immunostaining
against KCC2 and was looking for IL-1R1 immunoreac-
tive spots which were either aligned along lines defined
by the KCC2 immunostaining (localization in the cell
membrane) or located in areas surrounded by the
KCC2-immunostained cell membranes (localization in
the cytoplasm). After careful evaluation of the double-
stained sections, from the 1332 IL-1R1 immunoreactive
spots recovered from the nine investigated sections im-
munostained for KCC2, we found 264 (19.8 ± 2.27%)
within the somatodendritic membranes whereas 665
(49.9 ± 2.56%) of them were recovered in the cytoplasm
of neurons (Figs. 5e–g, 6).
Localization of IL-1R1 in postsynaptic densities of putative
excitatory and inhibitory synapses
Co-precipitation studies of Gardoni et al. [41] suggested
that IL-1R1 distributed along the somatodendritic
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Fig. 5 (See legend on next page.)
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membranes of hippocampal neurons are enriched in
postsynaptic membranes of excitatory synapses. Since
we found that approximately 20% of the IL-1R1 immu-
noreactive spots were scattered along the somatodendri-
tic membrane, we intended to test what proportions of
the receptor molecules can be inserted into the postsyn-
aptic membranes of putative excitatory and inhibitory
synapses. Thus, we were looking for IL-1R1 immunore-
active spots within the confines of PSD95, a postsynaptic
density protein characteristic for glutamatergic synapses
[83–85] and gephyrin, a scaffolding protein associated
with GABAA and glycine receptors [86–88], which are
immunoreactive postsynaptic membranes of putative ex-
citatory and inhibitory synapses, respectively.
In agreement with the report of Gardoni et al. [41], we
revealed a remarkable enrichment of IL-1R1 immunor-
eacitvity in some postsynaptic membranes of putative
excitatory synapses. After the evaluation of the nine
double-stained sections, we recovered 1122 PSD95 im-
munoreactive spots, putative postsynaptic membranes of
excitatory synapses, and found that 72 (6.4 ± 0.43%) of
them were also stained for IL-1R1. Most interestingly,
we recovered 117 IL-1R1 immunoreactive dots within
the confines of PSD95 immunoreactive postsynaptic
membranes representing 9.04 ± 0.43% of the total num-
ber of IL-1R1 immunoreactive spots (Figs. 5h–j and 6)
which is about half of the IL-1R1-immunostained spots
on the somato-dendtiric membrane of neurons. The
colocalization between gephyrin and IL-1R1 immuno-
staining was much lower. From the 1250 gephyrine im-
munoreactive postsynaptic membranes counted in the
sections, only 15 (1,2 ± 1.1%) was also stained for IL-
1R1, and the 26 IL-1R1 immunoreactive dots recovered
within the confines of gephyrin immunoreactive post-
synaptic membranes represented only 2.17 ± 0.3% of the
total number IL-1R1 immunoreactive spots (Figs. 5k–m
(See figure on previous page.)
Fig. 5 Localization of IL-1R1 on neurons and glial cells in the superficial spinal dorsal horn of rats. Micrographs of single 1-μmthick laser scanning
confocal optical sections illustrating the co-localization between immunolabeling for IL-1R1 (red; a–d, e, h, k, n, q) and immunoreactivity for
markers that are specific for axon terminals of peptidergic (CGRP, green; a) and non-peptidergic (IB4 binding, green; b) primary afferents, axon
terminals of excitatory (VGLUT2, green; c) and inhibitory (VGAT, green; d) intrinsic neurons, astrocytes (GFAP, green; o) and microglial cells
(CD11b, green; r), and postsynaptic membranes of excitarory (PSD95, green; i) and inhibitory (gephyrin, green; l) synapses in the superficial
spinal dorsal horn. Mixed colors (yellow; marked by white arrowheads) on the superimposed images (j, m, p, s) indicate double-labeled
structures. The absence of yellow color on a–d indicates a lack of IL-1R1 expression on axon terminals of various origin. IL-1R1 immunoreactive spots
appear in two different localization on the micrographs showing immunostaining also for KCC2 (green, f, g): (1) They can be aligned along the lines
defined by the KCC2 immunostaining (cell membrane localization; white arrowheads on f and g). (2) They can also be located in areas surrounded by
the KCC2-immunostained cell membranes (cytoplasmic localization, yellow arrowhead on g. Bars 2 μm (a–d), 5 μm (n–s), and 10 μm (e–m)
Fig. 6 Histogram showing the CFA-evoked inflammation induced changes in the degree of co-localization between immunoreactivity for IL-1R1
and selected neuronal and glial markers in the superficial spinal dorsal horn of rats. Columns indicate the percentages of profiles immunoreactive
for IL-1R1 that were found to be labeled also for the selected markers, and the ones that were aligned along KCC2 immunoreactive membranes
(localization on the somatodendritic membrane of neurons) or were located within areas surrounded by KCC2 immunoreactive membranes
(localization within the cytoplasm of the somatodendritic compartment of neurons). White columns show data obtained from control animals,
whereas black columns represent values found in CFA-injected animals 3 days after CFA injection into the right hind paw. Asterisk indicate that
CFA-evoked inflammation significantly increased the number of spots immunoreactive for IL-1R1 on the somato-denditic membrane of neurons
(p = 0.000001). Data are shown as mean ± SEM
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and 6) which is about 10% of the IL-1R1-immunostained
spots on the somato-dendtiric membrane of neurons.
Localization of IL-1R1 on astrocytes and microglial cells
To study the expression of IL-1R1 on astrocytes and
microglial cells, we investigated the co-localization of
the receptor with glial fibrillary acidic protein (GFAP)
and CD11b, markers that selectively label astrocytes and
microglial cells, respectively.
Evaluating the sections double-stained for IL-1R1 and
one of the glial markers we found, a low level of co-
localization with GFAP and almost a complete segrega-
tion between Il-1R1 and CD11b. From the 1350
and1330 IL-1R1 immunoreactive dots recovered from
the nine investigated sections immunostained for GFAP
and CD11b, only 125 (9.3 ± 0.65%) and 16 (1.2 ± 0.30%)
of IL-1R1 immunoreactive puncta were recovered on as-
trocytes and microglial cells immunoreactive for GFAP
and CD11b, respectively (Figs. 5n–s, and 6).
Overexpression of IL-1R1 on extrasynaptic somatodendritic
membrane compartments of neuron in CFA-evoked
inflammatory pain
We found a robust expression of IL-1R1 on the somato-
dendritic compartment of neurons, an enrichment of the
receptor in the postsynaptic membranes of some excita-
tory synapses and only a moderate one on astrocytes in
control animals. As we also demonstrated, inflammatory
pain evoked by CFA injection into the hind paw in-
creased the expression IL-1R1 in a substantial extent
3 days after the CFA injection, at the time of the summit
of hyperalgesia and allodynia. CFA-evoked inflammatory
pain, however, may modify not only the quantity but also
the distribution pattern of IL-1R1 in the superficial
spinal dorsal horn. Thus, we intended to explore how
the expression pattern observed in the control animals
may change in CFA-evoked inflammatory pain condi-
tion. For this reason, we repeated the complete set of
immunocytochemical double staining experiments on
sections obtained from CFA-injected experimental ani-
mals 3 days after the CFA injection.
The proportion of IL-1R1 immunoreactive spots re-
vealed on axon terminals and glial cells were found to
be very similar to the control values (Fig. 6); although,
concerning the increase in the quantity of IL-1R1, the
unchanged proportions may indicate a slight increase in
the total number of IL-1R1 both on axon terminals and
glial cells. In case of the somatodendritic compartment
of neurons, the proportion of IL-1R1 immunoreactive
spots did not show any change in the cytoplasm and on
postsynaptic membranes immunoreactive for PSD95 and
gephyrin either; although similarly to the axonal and
glial expression, the unchanged proportions may indicate
a slight increase in the total number of IL-1R1 in
postsynaptic membranes of both excitatory and inhibi-
tory synapses. The only obvious change in the distribu-
tion of IL-1R1 immunoreactivity that we observed at the
level of statistical significance was an increase in the
proportion of IL-1R1-immunostained dots that were
aligned along the lines defined by KCC2 immunostain-
ing, indicating a robust increase in the expression of IL-
1R1 on the somatodendritic membrane compartment of
neurons. In this case, the 19.8 ± 2.27% value of IL-1R1
immunoreactive spots which were aligned along the
lines defined by the KCC2 immunostaining in control
animals increased to 35.1 ± 1.5% (p = 0.002) (Fig. 6).
Discussion
Investigating the expression and cellular distribution of
IL-1R1 in the superficial spinal dorsal horn of rats in
control animals and also in CFA-evoked inflammatory
pain, we found a highly significant, approximately six
times increase in the IL-1R1 mRNA and a 1.5 times in-
crease in the IL-1R1 protein levels in the dorsal horn of
experimental animals ipsilateral to CFA injection on
post-injection day 3, at the time of the summit of the
mechanical and thermal sensitivity of the animals.
Underlying the importance of IL-1R1-mediated signaling
in the development of inflammatory pain, here we also
demonstrated that in the lack of IL-1R1, the develop-
ment of both mechanical and thermal allodynia evoked
by CFA injection into the hind paw becomes inhibited at
a considerable extent. Studying the cellular distribution
of IL-1R1 in rats, we found a robust expression of IL-
1R1 on the somatodendritic compartment of neurons
and an enrichment of the receptor in the postsynaptic
membranes of some excitatory synapses. In contrast to
the abundant neuronal localization, we observed only a
moderate expression of IL-1R1 on astrocytes and almost
nothing on microglial cells. CFA injection into the hind-
paw caused a remarkable increase in the expression of
IL-1R1 on the somatodendritic membrane of neurons,
but did not alter the glial expression of the receptor.
IL-1R1-mediated signaling mechanisms play a major role
in spinal pain processing
It is well established that the pro-inflammatory cytokine
IL-1β facilitates the transmission and processing of nox-
ious inputs at the spinal level [4, 6]. Further support to
this idea is provided by studies showing that intrathecal
administration of IL-1β in healthy rodents induces
hyperalgesia and allodynia [16–21, 89] and enhance both
the acute response to C-fiber stimulation and the wind-
up activity of dorsal horn neurons [15, 22]. IL-1β is
reported to be upregulated in the spinal cord during in-
flammatory [4, 6, 7, 23] and neuropathic pain [11, 12]
which led to the notion that IL-1β can be an important
contributor to the development of persistent pain states
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[7, 9, 21, 28]. All known biological functions of IL-1β are
mediated by IL-1R1 [34]. IL-1R1 antagonist (IL-1Ra)
completely abolish IL-1β-induced enhancement of no-
ciceptive neuron responses [90] and produce anti-
allodynic effects in rat model of neuropathic [91, 92],
inflammatory [9], and cancer pain [8, 13, 21].
Along this line of evidence, here we showed that not
only IL-1β but also IL-1R1 mRNA as well as protein
levels also became substantially upregulated in the spinal
dorsal horn in CFA-evoked inflammatory pain condition.
This is a quite remarkable novel finding since the in-
creased expression of IL-1R1 is likely to be necessary for
the enhancement of the effects of IL-1β in persistent
pain conditions. The increased expression of IL-1R1 and
the consecutive enhancement of the Il-1β–IL-1R1 sig-
naling mechanisms seem to be one of the most import-
ant contributors to the development of spinal central
sensitization and the following chronic inflammatory
pain condition, since in the lack of the receptor the de-
velopment of both mechanical and thermal allodynia
evoked by CFA injection into the hind paw becomes
inhibited at a considerable extent, as we showed here.
This notion is strongly reinforced by the finding of Wolf
et al. [93] reporting that neuropathic pain was also
markedly reduced with the deletion of IL-1R1 or trans-
genic overexpression of IL-1Ra.
Neuronal expression of IL-1R1 dominates over glial
localization in the superficial spinal dorsal horn
According to the prevailing view, the effects of IL-1β
on spinal pain processing are mediated by direct ac-
tions on neurons [47–49] through its specific receptor
[9, 28, 30, 40]. Consistent with this notion, we recov-
ered more than two-thirds of IL-1R1 immunostaining
on the somatodendritic compartment of neurons in
control rats. Concerning the concept of direct action
of IL-1β on neurons, it is even more remarkable that
the CFA-evoked inflammatory pain condition further
increased the somatodendritic expression of IL-1R1.
Three days after CFA injection into the hind-paw, ap-
proximately 85% of IL-1R1 immunostaining was ob-
served in the somatodendritic compartment of
neurons. Even more importantly, this increase was
mostly due to the abundant expression of IL-1R1 on
the somatodendritic membrane.
The activation of neuronal IL-1R1 initiates phosphor-
ylation of NR1 and/or NR2B subunits of NMDA recep-
tors [9, 28] contributing to the trafficking of NMDA
receptors to the cell membrane [94]. The insertion of
additional NMDA receptors into postsynaptic mem-
branes enhances NMDA receptor-mediated inward cur-
rents and increases intracellular Ca2+ concentration
[26, 27, 30] leading to the facilitation of nociceptive C-
fiber stimulation [21, 44, 95, 96], wind-up phenomena
[97], post-discharge of wind-dynamic range neurons in
the spinal dorsal horn [15, 21], and consecutively to the
development of LTP, central sensitization, and pain
[98]. Our present results indicate that synaptic NMDA
receptors and glutamatergic synaptic transmission can
be influenced by IL-1R1 located both in the postsynap-
tic and extrasynaptic membranes. In agreement with
the findings of Gardoni et al. [41], we found that in
control rats, nearly half of the IL-1R1 immunostaining
recovered on the somatodendritic membrane of neu-
rons was co-localized with PSD95, one of the postsyn-
aptic density protein of glutamatergic synapses [83–85].
However, this enrichment of IL-1R1 was found only in
a minor fraction of glutamatergic synapses. Only 6–7%
of PSD95-immunostained spots were also stained for
IL-1R1. If we assume that a larger population of gluta-
matergic synapses can be modulated by the activation
of IL-1R1, as it is indicated by the aforementioned
functional studies, the activation of extrasynaptic IL-
1R1 should be considered also effective concerning the
potentiation of NMDA receptors similarly to the synap-
tic ones. This notion is strongly supported by another
finding of the present experiments, showing that the
relative proportion of IL-1R1 expression 3 days after
CFA injection into the hind paw nearly doubled on the
somatodentritic membrane but the co-localization of
the receptor with PSD95 was found to be unchanged.
Here we also demonstrated that in addition to excita-
tory synapses, IL-1R1 was also located in postsynaptic
membranes of inhibitory synapses. We found that ap-
proximately 10% of IL-1R1 immunostaining on the
somatodendritic membrane of neurons was co-localized
with gephyrin, a scaffolding protein within the postsyn-
aptic membrane of inhibitory synapses [86–88]. In the
light of the report of Chirila et al. [99], showing that in
the superficial spinal dorsal horn glycinergic synapses on
inhibitory GABAergic, neurons exhibit LTP, occurring
rapidly after exposure to the inflammatory cytokine IL-
1β, it is likely that the gephyrin-immunostained spots
found to be positive also for IL-1R1 in the present study
represent glycinergic synapses. Although we observed
IL-1R1 immunostaining only in approximately 1% of
gephyrin-immunostained spots, one can regard this find-
ing functionally significant, since the potentiation of gly-
cinergic synapses on GABAergic neurons evoked by in
vitro bath application of IL-1β [21, 100] or peripheral in-
flammation in vivo [99] could evoke considerable dis-
inhibition in pain processing spinal neural networks
[21, 101], an important mechanism that is increas-
ingly appreciated for the generation of chronic pain
[102, 103].
Although the prevailing view assumes that IL-1β is
directly acting on neurons, some authors claim that the
synaptic effects of IL-1β are not mediated directly via
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activation of neuronal IL-1R1, but rather, indirectly via
IL-1R1 being expressed on glial cells in the superficial
spinal dorsal horn [43, 45, 46, 104]. In support of this
hypothesis, Gruber-Schoffnegger et al. [45] reported that
in the presence of fluorocitrate, an inhibitor of glial meta-
bolism, IL-1β depressed, rather than potentiated, NMDA
receptor-mediated currents, suggesting that IL-1β needs to
activate glia to facilitate glutamatergic transmission at C-
fiber synapses. According to this alternative assumption,
activation of glial IL-1R1 by IL-1β leads to the release of
gliotransmitters which may amplify glutamatergic synaptic
transmission. Our present results, although emphasizes
the direct neuronal action of Il-1β, does not provide any
evidence against the possibility of the action of IL-1β on
glial IL-1R1. In the present study, we found that nearly
10% of IL-1R1 immunostaining was localized on astro-
cytes, but we were not able to detect any substantial
immunolabeling on microglial cells.
Conclusions
In conclusion, we may speculate that due to their activa-
tion by peripheral inflammation nociceptive primary af-
ferents release ATP in the spinal dorsal horn [105]. ATP
acting on glial adenosine receptors [106] initiates IL-1β
release from astrocytes [8–10, 45]. IL-1β binds to neu-
ronal IL-1R1, the activation of which amplifies NMDA
receptor-mediated synaptic currents [9, 28] and potenti-
ates glycinergic synapses on GABAergic neurons [99],
thus reducing inhibitory synaptic transmission. In addition,
IL-1β also interacts with IL-1R1 expressed by astrocytes
[45]. In response to this, astrocytes release gliotransmitters
[50, 51] which may further facilitate glutamatergic trans-
mission. These diverse signaling cascades acting in concert
with each other can substantially contribute to the en-
hancement of the excitation level of spinal pain processing
neural networks leading to the development of spinal cen-
tral sensitization and consecutive pain.
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